Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, announced terms for its IPO on Friday.
The Houston, TX-based company plans to raise $25 million by offering 1.9 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Kiromic BioPharma would command a fully diluted market value of $119 million.
Kiromic's pipeline consists of four early-stage product candidates targeting blood cancers and solid tumors. Kiromic utilizes its proprietary target discovery platform, Diamond, to identify new cancer immunological targets for T cells and B cells. The company is also developing a non-viral gene editing mechanism, called ABBIE (A Binding-Based Integrase Enzyme), for delivering its product candidates.
Kiromic BioPharma was founded in 2006 and plans to list on the NYSE American under the symbol KRBP. ThinkEquity is the sole bookrunner on the deal.
The article Immuno-oncology biotech Kiromic BioPharma sets terms for $25 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
